Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine- and AMP-induced bronchoconstriction

Salmeterol provides bronchoprotection against a number of constrictor stimuli for more than 12 h after a single dose. This effect could be due either to functional antagonism at the level of airway smooth muscle or to cell-stabilizing effects of the compound. In this study, we attempted to clarify this mechanism by comparing the effects of salmeterol (50 micrograms), salbutamol (200 micrograms) and placebo on the airway responsiveness to histamine (to assess functional antagonism), and to adenosine 5'-monophosphate (AMP) (to assess additional cell-stabilizing effects), 14 h after drug treatment. Thirteen patients with mild allergic asthma were studied in a double-blind, randomized protocol on 6 days, at least 48 h apart. Forced expiratory volume in one second (FEV1) was measured before and 15 min after inhalation of the study medication. Then, 14 h later (8 a.m. the following morning), a bronchoprovocation test with histamine or AMP was performed. We found that 14 h after inhalation, salmeterol still had a significant effect on FEV1 in comparison to placebo and salbutamol. The provocative dose producing a 20% fall in FEV1 (PD20histamine) was significantly increased after salmeterol, whilst the increase in PD20AMP did not reach significance. The shift in PD20 (in doubling dose steps) induced by salmeterol pretreatment was not different between histamine and AMP. We conclude that the prolonged protective effect of salmeterol occurs via an extended bronchodilating and functional antagonistic action and not via a cell-stabilizing effect.

This article has been cited by other articles:

				L. Prieto, C. Badiola, J. Cortijo, C. Perez-Frances, V. Gutierrez, and A. Lanuza Phenol-Containing Saline Solution as a Diluent for Adenosine 5'-Monophosphate in Bronchial Challenge Testing Chest, January 1, 2005; 127(1): 125 - 130. [Abstract] [Full Text] [PDF]

				R.I. Ketchell, M.W. Jensen, D. Spina, and B.J. O'Connor Dose-related effects of formoterol on airway responsiveness to adenosine 5'-monophosphate and histamine Eur. Respir. J., April 1, 2002; 19(4): 611 - 616. [Abstract] [Full Text] [PDF]

				J. C. KIPS and R. A. PAUWELS Long-acting Inhaled beta 2-Agonist Therapy in Asthma Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932. [Full Text] [PDF]

				X. LI, C. WARD, F. THIEN, R. BISH, T. BAMFORD, X. BAO, M. BAILEY, J. W. WILSON, and E. HAYDN WALTERS An Antiinflammatory Effect of Salmeterol, a Long-acting beta 2 Agonist, Assessed in Airway Biopsies and Bronchoalveolar Lavage in Asthma Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1493 - 1499. [Abstract] [Full Text]

				J. A. NIGHTINGALE, D. F. ROGERS, and P. J. BARNES Differential Effect of Formoterol on Adenosine Monophosphate and Histamine Reactivity in Asthma Am. J. Respir. Crit. Care Med., June 1, 1999; 159(6): 1786 - 1790. [Abstract] [Full Text]

				D. Taylor, M. Jensen, S. Aikman, J. Harris, P. Barnes, and B. O'Connor Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma Am. J. Respir. Crit. Care Med., December 1, 1997; 156(6): 1731 - 1737. [Abstract] [Full Text]

				D. H. YATES, M. WORSDELL, and P. J. BARNES Effect of Regular Salmeterol Treatment on Albuterol-induced Bronchoprotection in Mild Asthma Am. J. Respir. Crit. Care Med., September 1, 1997; 156(3): 988 - 991. [Abstract] [Full Text] [PDF]